Table 2.

Carotid intimamedia thickness and inflammatory markers at baseline and 12 weeks after the intervention in patients with polycystic ovary syndrome

	Placebo group (n=30)				Carnitine group (n=30)				P#
	Baseline	End-of-trial	Change	P*	Baseline	End-of-trial	Change	P*
Mean left CIMT (mm)	0.48±0.04	0.48±0.05	0.001±0.01	0.47	0.49±0.05	0.47±0.05	−0.01±0.02	0.001	0.001
Maximum left CIMT (mm)	0.58±0.05	0.58±0.05	0.002±0.006	0.07	0.58±0.06	0.57±0.04	−0.01±0.02	0.005	0.001
Mean right CIMT (mm)	0.47±0.04	0.47±0.04	0.002±0.01	0.33	0.49±0.06	0.48±0.05	−0.01±0.02	0.001	0.001
Maximum right CIMT (mm)	0.57±0.05	0.57±0.04	0.006±0.01	0.04	0.59±0.06	0.57±0.04	−0.01±0.02	0.002	<0.001
hs-CRP (ng/mL)	3030.0±1380.2	3300.3±1283.3	270.3±752.7	0.05	3116.7±2549.5	3121.9±3188.0	5.1±2016.5	0.89	0.50
NO (μmol/L)	42.2±5.4	42.4±5.0	0.2±2.3	0.64	43.2±5.4	45.7±4.4	2.4±3.6	0.001	0.007

*P values represent paired-samples t-test, ^#P values represent the time×group interaction (computed by analysis of the one-way repeated measures ANOVA), all values are means±SDs. CIMT=Carotid intima-media thickness, hs-CRP=High-sensitivity C-reactive protein, NO=Nitric oxide, SD=Standard deviation, ANOVA=Analysis of variance